FDA-Approved Phase IIb Trial Underway in U.S. to Treat Critical Limb Ischemia

ANN ARBOR, Mich., March 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a company developing cell-based therapeutics for regenerative medicine, today announced that Gerald D. Brennan, Jr., Vice President, Administrative & Financial Operations and

-- Additional Positive Patient Treatment Results Presented at the American Academy of Orthopaedic Surgeons Meeting --

ANN ARBOR, Mich., Feb 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a company developing cell-based therapeutics for regenerative medicine, today reported financial results for the second fiscal quarter ended December 31, 2006.

ANN ARBOR, Mich., Feb 02, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. 2nd Quarter Fiscal Year 2007 Investor Conference Call When: Wednesday, February 7, 2007 @ 9:00 am (EST) Where:

- Up to 150,000 People in U.S. Currently Suffer from this Severe Chronic Heart Disease

- Pivotal Bone Regeneration Trial Underway in Spain -

-- Appointment Supports New Initiatives --

Aastrom Biosciences to Present at RBC Capital Markets Healthcare Conference Ann Arbor, Michigan, December 7, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM), a clinical development stage company focused on the use of autologous cells for regenerative medicine, today announced that George W.

Aastrom Biosciences to Present at BMO Capital Markets Healthcare Conference Ann Arbor, Michigan, November 30, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) ), a clinical development stage company focused on the use of autologous cells for regenerative medicine, today announced that George W.